

OVER THE COUNTER AT-HOME TESTS FOR COVID-19 from The Medical Letter®

Antigen Tests						
Test	Authorized Ages	Test Regimen/ Time for Result	PPA/NPA¹	Requires Mobile App?	Teleprovider Monitoring Available?	Cost²
<i>BD Veritor At-Home COVID-19 Test (BD)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Symptomatic: 85%/100%	Yes	No	\$35.00 (2 ct) ¹¹
<i>BinaxNOW COVID-19 Antigen Self-Test (Abbott)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Overall: 98%/96% Symptomatic: 100%/91% Asymptomatic: 92%/97% ³	No ⁴	Yes ⁴	14.00 (2 ct)
<i>CareStart COVID-19 Antigen Home Test¹⁴ (Access Bio)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 10 minutes	Overall: 87%/98%	Yes	No	24.00 (2 ct) ⁸
<i>Celltrion DiaTrust COVID-19 Ag Home Test (Celltrion)</i>	≥14 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Overall: 87%/100% Symptomatic: 86%/99% Asymptomatic: 89%/100%	Yes	No	20.00 (2 ct) ¹²
<i>Clinitest Rapid COVID-19 Antigen Self-Test (Siemens)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Symptomatic: 87%/99%	No	No	N/A
<i>Ellume COVID-19 Home Test (Ellume)</i>	≥2 years	Single test/15 minutes	Overall: 95%/97% Symptomatic: 96%/100% Asymptomatic: 91%/96%	Yes	Yes	39.00 (1 ct) ⁵
<i>Flowflex COVID-19 Home Antigen Test (ACON)</i>	≥2 years	Single test/15 minutes	Overall: 93%/100% Symptomatic: 93%/100% Asymptomatic: 92%/100%	No	No	10.00 (1 ct) ⁵
<i>iHealth COVID-19 Antigen Rapid Test (iHealth)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Symptomatic: 94%/98% Asymptomatic: 85-88%/N.D.	Yes	No	20.00 (2 ct) ⁵
<i>Indicaid COVID-19 Rapid Antigen At-Home Test (Phase Scientific)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 20 minutes	Symptomatic: 82%/99%	No	No	N/A
<i>InteliSwab COVID-19 Rapid Test (Orasure)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 30 minutes	Symptomatic: 84%/98%	No	No	20.00 (2 ct)
<i>MaximBio ClearDetect COVID-19 Antigen Home Test (Maxim Biomedical)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-36 hrs (asymptomatic)/ 15 minutes	Symptomatic: 87%/99%	No	No	24.00 (2 ct) ⁹
<i>OHC Covid-19 Antigen Self-Test (Osang)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Symptomatic: 83%/99% ¹⁵	No	No	N/A
<i>Pilot COVID-19 At-Home Test (SD Biosensor)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 20 minutes	Symptomatic: 100%/95%	No	No	N/A
<i>QuickVue At-Home OTC COVID-19 Test (Quidel)</i>	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 10 minutes	Overall: 84%/99%	No	No	24.00 (2 ct)

Continued on next page

OVER THE COUNTER AT-HOME TESTS FOR COVID-19 from The Medical Letter®

Antigen Tests (continued)						
Test	Authorized Ages	Test Regimen/ Time for Result	PPA/NPA¹	Requires Mobile App?	Teleprovider Monitoring Available?	Cost²
<i>Rapid SARS-CoV-2 Antigen Test Card</i> (Xiamen Boson)	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 15 minutes	Symptomatic: 83%/99% ¹⁵	No	No	N/A
<i>SCoV-2 Ag Detect Rapid Self-Test</i> (InBios)	≥2 years	Single test (symptomatic) or 2 tests over 24-48 hrs (asymptomatic)/ 20 minutes	Symptomatic: 86%/100%	No	No	N/A
Molecular Tests						
<i>Cue COVID-19 Test for Home and OTC Use</i> (Cue)	≥2 years	Single test/20 minutes	Overall: 97%/99% Symptomatic: 96%/98% Asymptomatic: 100%/100%	Yes	No	\$195.00 (3 ct) ¹⁰
<i>Detect Covid-19 Test</i> (Detect)	≥2 years	2 tests over 24-48 hrs/55 minutes	Overall: 91%/98%	Yes	No	49.00 (1 ct) ¹³
<i>Lucira CHECK-IT COVID-19 Test Kit</i> (Lucira)	≥2 years	Single test/30 minutes	Overall: 92%/98% Symptomatic: 94%/98% Asymptomatic: 90%/98%	No	Yes ⁶	75.00 (1 ct) ⁷

N/A = not currently commercially available; N.D. = no data available

- Positive percent agreement/negative percent agreement with RT-PCR test, as described in the products' instructions for use. According to the FDA, early data suggest that antigen tests may have reduced sensitivity to the Omicron variant of SARS-CoV-2 (<https://bit.ly/3sPZiup>; accessed January 3, 2022).
- Cost at [walmart.com](https://www.walmart.com). Accessed April 18, 2022.
- JL Prince-Guerra et al. *MMWR Morb Mortal Wkly Rep* 2021; 70:100.
- The *BinaxNOW COVID-19 Antigen Self-Test* does not require a mobile app and is not compatible with teleprovider monitoring. The same test is also marketed as the *BinaxNOW COVID-19 Ag Card Home Test*, which does require a mobile app and is compatible with teleprovider monitoring.
- Cost at [cvs.com](https://www.cvs.com). Accessed April 18, 2022.
- Requires user to send text message from smartphone to access *Luci Pass* verification portal.
- Cost at [checkit.lucirahealth.com](https://www.checkit.lucirahealth.com). Accessed January 3, 2022.
- Cost at [riteaid.com](https://www.riteaid.com). Accessed January 3, 2022.
- Cost at [thomassci.com](https://www.thomassci.com). Accessed April 18, 2022.
- Cost at [shop.cuehealth.com](https://www.shop.cuehealth.com). Requires additional purchase of test reader (\$249.00). Accessed April 18, 2022.
- Cost at [everlywell.com](https://www.everlywell.com). Accessed January 3, 2022.
- Cost at [medidentsupplies.com](https://www.medidentsupplies.com). Accessed April 18, 2022.
- Cost at [detect.com](https://www.detect.com). Requires additional purchase of test reader (\$39.00). Accessed January 3, 2022.
- Also marketed as the *On/Go COVID-19 Antigen Self-Test*.
- Data were adjusted to reflect results from a sample population in which 10% of patients were symptomatic with low viral loads, similar to sample populations in studies of other antigen tests that were performed before the Omicron variant of SARS-CoV-2 became dominant.

To support more content like this,
please consider making a donation* or becoming a subscriber.

The Medical Letter®
Because the source matters.

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

Subscribe for less than \$3/week.

* Medical Letter, Inc. (EIN: 13-1881832) is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.

PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; ASSOCIATE EDITORS: Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. CONSULTING EDITORS: Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; EDITORIAL ASSISTANT: Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; EXECUTIVE DIRECTOR OF SALES: Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; INTERIM PUBLISHER: Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-732X

The
Medical
Letter